| Stereochemistry | RACEMIC |
| Molecular Formula | C20H17F3N2O4 |
| Molecular Weight | 406.3552 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OCC(O)COC(=O)C1=C(NC2=C3C=CC=C(C3=NC=C2)C(F)(F)F)C=CC=C1
InChI
InChIKey=APQPGQGAWABJLN-UHFFFAOYSA-N
InChI=1S/C20H17F3N2O4/c21-20(22,23)15-6-3-5-13-17(8-9-24-18(13)15)25-16-7-2-1-4-14(16)19(28)29-11-12(27)10-26/h1-9,12,26-27H,10-11H2,(H,24,25)
| Molecular Formula | C20H17F3N2O4 |
| Molecular Weight | 406.3552 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Floctafenine is an analgesic agent used for the treatment of pain. The drug exerts its anti-inflammatory action by inhibiting COX-1 and COX-2, with a slight preference towards COX-1. Floctafenine is marketed in Canada under the name Floctafenine and it is withdrawn in Europe (Idarac Brand name).
Originator
Approval Year
Doses
AEs
PubMed
Sample Use Guides
The usual adult dose of floctafenine is 200 to 400 mg every 6 to 8 hours as required. The maximum recommended daily dose is 1200 mg.
Route of Administration:
Oral
The effects of floctafenine and its active metabolite on platelet COX-1, monocyte and 5-LO activities of whole blood in vitro were assessed by incubating increasing concentrations of floctafenine or floctafenic acid (0.001-100 mM) with peripheral whole blood samples drawn from healthy volunteers.
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
Showing 1 to 2 of 2 entries
Showing 1 to 2 of 2 entries
